5-butynyl-dUrd | 77875-96-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 5-butynyl-dUrd
• 英文别名: 5-(but-1-ynyl)-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione；5-but-1-ynyl-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• CAS: 77875-96-8
• 化学式: C₁₃H₁₆N₂O₅
• 分子量: 280.28
• InChiKey: PXCHYHBELCFZQQ-HBNTYKKESA-N

物化性质

• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-iodo-3',5'-di-O-p-toluyl-2'-deoxyuridine 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 sodium methylate 作用下， 以 甲醇 、 三乙胺 为溶剂， 反应 10.0h， 生成 5-butynyl-dUrd
  参考文献：
  名称：

  核酸相关化合物。31.末端炔烃与5-碘尿嘧啶核苷的平滑高效钯钯催化偶联

  摘要：

  在三乙胺中存在二氯双（三苯基膦）钯和碘化铜（I）的情况下，末端炔烃与受保护的5-碘尿嘧啶核苷的偶联以72-92％的收率得到相应的5-（炔-1-基）尿嘧啶核苷。

  DOI：

  10.1016/0040-4039(81)80115-3

文献信息

• Nucleic acid related compounds. 31. Smooth and efficient palladium-copper catalyzed coupling of terminal alkynes with 5-iodouracil nucleosides
  作者：Morris J. Robins、Philip J. Barr

  DOI：10.1016/0040-4039(81)80115-3

  日期：1981.1

  Coupling of terminal alkynes with protected 5-iodouracil nucleosides in the presence of dichlorobis(triphenylphosphine)palladium and copper(I) iodide in triethylamine gives the corresponding 5-(alkyn-1-yl)uracil nucleosides in 72–92% yields.

  在三乙胺中存在二氯双（三苯基膦）钯和碘化铜（I）的情况下，末端炔烃与受保护的5-碘尿嘧啶核苷的偶联以72-92％的收率得到相应的5-（炔-1-基）尿嘧啶核苷。
• STABILIZED NUCLEIC ACID DARK QUENCHER-FLUOROPHORE PROBES
  申请人：Cook Ronald M.

  公开号：US20090259030A1

  公开（公告）日：2009-10-15

  The present invention provides a new class of solids supports for synthesis of modified oligomers of nucleic acids, and nucleic acid probes that have a format expediently synthesized on the new supports. Exemplary solid supports include at least one quencher bound through a linker to the solid support. Various exemplary embodiments include a moiety that stabilizes a duplex, triplex or higher order aggregation (e.g., hybridization) of nucleic acids of which the oligomer of the invention is a component. Other components of the solid support include moieties that stabilize aggregations of nucleic acids, e.g., intercalators, minor groove binding moieties, bases modified with a stabilizing moiety (e.g., alkynyl moieties, and fluoroalkyl moieties), and conformational stabilizing moieties, such as those described in commonly owned U.S. Patent Application Publication No. 2007/0059752.

  本发明提供了一种新型固体支持体，用于合成修饰寡核苷酸的新类固体支持体以及具有在新支持体上方便合成的核酸探针。示例固体支持体包括至少通过连接剂与固体支持体结合的一个猝灭剂。各种示例实施例包括稳定双链、三链或更高级别聚集（例如，杂交）的基团，其中该发明的寡聚物是其中的一个组分的基团。固体支持体的其他组分包括稳定核酸聚集的基团，例如，插入剂、小沟结合基团、经过稳定基团修饰的碱基（例如，炔基基团和氟烷基团）和构象稳定基团，例如，如同在共同拥有的美国专利申请公开号2007/0059752中描述的那样。
• Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
  申请人：——

  公开号：US20030170680A1

  公开（公告）日：2003-09-11

  Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention. Compositions of the invention can be used as pharmaceutical agents to treat various diseases such as those caused by viruses and can be used for diagnostic purposes in order to detect viruses or disease conditions.

  本发明揭示了一种新型寡聚物，与仅含传统碱基的寡聚物相比，具有增强的形成双链或三链的能力。该寡聚物包含5-（1-丙炔基）尿嘧啶，5-（1-丙炔基）胞嘧啶或相关类似物的碱基。本发明的寡聚物能够（i）通过在生理pH值下与靶DNA双链的主沟结合，形成与各种靶序列（如病毒或癌基因序列）的三链，或（ii）通过结合单链DNA或靶基因编码的RNA而形成双链。本发明的寡聚物可以被纳入药学可接受的载体中，并且可以构建任何所需的序列，只要序列通常包括一个或多个被本发明类似物替换的碱基。本发明的组合物可以用作制药剂治疗各种由病毒引起的疾病，并可用于诊断目的，以检测病毒或疾病情况。
• ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES
  申请人：——

  公开号：US20040265802A9

  公开（公告）日：2004-12-30

  Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention. Compositions of the invention can be used as pharmaceutical agents to treat various diseases such as those caused by viruses and can be used for diagnostic purposes in order to detect viruses or disease conditions.

  本发明披露了一种新型寡聚物，与仅含传统碱基的寡聚物相比，其具有增强的双链或三链形成能力。该寡聚物包含碱基5-(1-丙炔基)尿嘧啶，5-(1-丙炔基)胞嘧啶或相关类似物。本发明的寡聚物能够(i)在生理pH下通过耦合到目标DNA双链的主沟槽形成三链，如病毒或癌基因序列，或(ii)通过结合到单链DNA或由目标基因编码的RNA形成双链。本发明的寡聚物可以被纳入到药学可接受的载体中，并且可以构建任何所需的序列，只要该序列通常包括一个或多个被本发明的类似物替换的碱基。本发明的组合物可以用作制药剂治疗各种疾病，如由病毒引起的疾病，并且可以用于诊断目的，以检测病毒或疾病情况。
• Oligomers containing modified pyrimidines
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：EP1256589A2

  公开（公告）日：2002-11-13

  An oligomer comprising at least two nucleomonomers and pharmaceutically acceptable salts thereof wherein at least one of said nucleomonomers comprises a base of formula (1) or (2): wherein each X is independently O or S; R2 is a group comprising at least one pi bond connected to the carbon atom attached to the base; Pr is (H)2 or a protecting group;    with the proviso that when at least one of said nucleomonomers of said oligomer comprises deoxyuridine 5-substituted by vinyl, 1-butenyl, 1-pentenyl, 1-hexenyl, 1-heptenyl, 1-octenyl, 1-propynyl, 1-butynyl, 1-hexynyl, 1-heptynyl, or 1-octynyl, then the remainder of the nucleomonomers comprising said oligomer are not solely comprised of phosphodiester linked 2'-deoxyadenosine, 2'deoxyguanosine, 2'-deoxycytidine, thymidine or a combination thereof; and wherein said oligomer includes at least one unit having one of thirteen specific formulas.

  由至少两种核单体及其药学上可接受的盐组成的低聚物，其中至少一种核单体包括式 (1) 或 (2) 的碱： 其中每个 X 独立地为 O 或 S； R2 是一个基团，包含至少一个与连接到碱的碳原子相连的π键； Pr 是 (H)2 或保护基团； 1-庚炔基、1-庚炔基、1-辛炔基、1-丙炔基、1-丁炔基、1-己炔基、1-庚炔基或 1-辛炔基，则组成所述低聚物的核单体的其余部分并非仅由磷酸二酯连接的 2'-脱氧腺苷、2'-脱氧鸟苷、2'-脱氧胞苷、胸腺嘧啶或其组合组成；其中所述低聚物包括至少一个具有十三种特定公式之一的单元。